An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients

• Status: Completed
• Trial end date: 1969-12-31

Summary

This clinical study was designed to demonstrate that a single, intravenous dose of palonosetron 0.25 mg was not inferior to granisetron 3 mg in preventing acute and delayed CINV and was also well tolerated in the Chinese cancer patients.

• Phase: Phase 2

Details

• Lead Sponsor: Xijing Hospital
• Treatments: Granisetron; Palonosetron